CHICAGO · HEALTHTECH
The Profile
Eric
Meizlish
He wants to know the pressures inside your heart - and he plans to find out without ever going in.
He wants to know the pressures inside your heart - and he plans to find out without ever going in.
For decades, the only way to truly know the pressures and volumes inside a beating heart was to thread a catheter into it. Eric Meizlish took the top job at Cardiosense in September 2025 with a different idea: let an algorithm read the heart from the outside. The company's CardioTag sensor, cleared by the FDA in the summer of 2025, listens to the body's signals and predicts what was once measurable only by going in.
That is the bet Meizlish now runs. He succeeded co-founder Amit Gupta, who moved to chief strategy officer, and inherited a team of engineers, clinicians and biosignal scientists assembled around one stubborn problem - how to catch heart failure before it announces itself. His job is less invention than scale: turning a rare technical capability into something that reaches patients and the doctors who treat them.
“Our team has created a technical capability that has never existed before,” he said on taking the role - the ability to predict volumes and pressures within the heart, non-invasively. The next chapter, in his words, is about delivering those measures to patients and providers “at a moment when the industry is ready to embrace AI and digital solutions for heart health.”
It is the kind of problem Meizlish keeps walking toward. His career reads like a series of bets on clinical truth over clinical noise - on the idea that healthcare gets better when you measure the right thing well.
High standards must apply to the whole operation - simply because they are contagious.- Eric Meizlish, on what healthcare can learn from Amazon
The pitch is deceptively simple - put a sensor on the body, let the math do what a hospital procedure used to.
The CardioTag wearable captures the body's cardiac signals non-invasively.
AI-driven algorithms turn raw biosignals into clinical measures.
The platform estimates pressures and volumes inside the heart.
Clinicians get actionable insight - no costly implantable sensor required.
Trading desk, analytics firm, procurement platform, cardiac sensor. The throughline is healthcare that runs on better information.
He began his career investing in publicly traded technology, media and telecom companies - learning to separate signal from story before he ever ran one.
Co-founder, president and chief strategy officer of the clinical-evidence and analytics firm (born as Procured Health) that helped hospitals decide what actually works. Acquired by GHX in 2020.
After the acquisition he joined the GHX global leadership team as SVP of strategy and corporate development.
Became CEO in January 2024 of the cloud eProcurement platform built for the life-sciences industry.
Named CEO in September 2025 to scale an AI-enabled, non-invasive cardiac monitoring platform.
Sits on the investment committee funding emerging not-for-profits across the Chicago area, and advises growth-stage healthtech startups.
Invests in public technology, media and telecom names. (Earlier, an undergrad intern at the Yale Investments Office.)
President and chief strategy officer of the clinical analytics company.
Joins the GHX global leadership team as SVP, strategy & corporate development.
Takes the helm of the life-sciences procurement platform.
Cardiosense lands FDA clearance for non-invasive cardiac monitoring.
Succeeds co-founder Amit Gupta to lead the next phase of scale.
Democratize precision cardiac care - actionable insight, no costly implant.- the goal he's set for Cardiosense